Sinew Pharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Revenue	0.05	-	-	0.33	6.23	Upgrade
Revenue Growth (YoY)	-	-	-	-94.73%	1248.27%	Upgrade
Cost of Revenue	0.01	-	-	0.04	1.14	Upgrade
Gross Profit	0.04	-	-	0.29	5.09	Upgrade
Selling, General & Admin	42.69	36.95	34.75	34.1	26.77	Upgrade
Research & Development	97.47	131.91	151.51	114.62	72.75	Upgrade
Operating Expenses	140.16	168.86	186.25	148.72	99.51	Upgrade
Operating Income	-140.13	-168.86	-186.25	-148.43	-94.42	Upgrade
Interest Expense	-0.66	-0.41	-0.78	-0.28	-0.15	Upgrade
Interest & Investment Income	16.19	16.66	16.03	8.37	2.95	Upgrade
Other Non Operating Income (Expenses)	0.85	2.25	0.08	0.15	0.04	Upgrade
Pretax Income	-123.75	-150.37	-170.92	-140.18	-91.58	Upgrade
Net Income	-123.75	-150.37	-170.92	-140.18	-91.58	Upgrade
Net Income to Common	-123.75	-150.37	-170.92	-140.18	-91.58	Upgrade
Shares Outstanding (Basic)	71	71	70	69	59	Upgrade
Shares Outstanding (Diluted)	71	71	70	69	59	Upgrade
Shares Change (YoY)	-0.37%	1.21%	1.68%	16.47%	19.41%	Upgrade
EPS (Basic)	-1.74	-2.11	-2.43	-2.02	-1.54	Upgrade
EPS (Diluted)	-1.74	-2.11	-2.43	-2.02	-1.54	Upgrade
Free Cash Flow	-95.93	-106.26	-125.26	-98.99	-59.5	Upgrade
Free Cash Flow Per Share	-1.35	-1.49	-1.78	-1.43	-1.00	Upgrade
Gross Margin	78.72%	-	-	88.41%	81.75%	Upgrade
Operating Margin	-298140.43%	-	-	-45252.44%	-1515.81%	Upgrade
Profit Margin	-263287.23%	-	-	-42737.81%	-1470.14%	Upgrade
Free Cash Flow Margin	-204112.77%	-	-	-30178.66%	-955.19%	Upgrade
EBITDA	-127.14	-144.98	-163.63	-128.29	-73.88	Upgrade
D&A For EBITDA	12.99	23.88	22.62	20.13	20.55	Upgrade
EBIT	-140.13	-168.86	-186.25	-148.43	-94.42	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.